HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.

Détails

Ressource 1Télécharger: 26152237_BIB_9BB88EAC412E.pdf (590.85 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_9BB88EAC412E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Périodique
Bmc Gastroenterology
Auteur(s)
Bihl F., Martinetti G., Wandeler G., Weber R., Ledergeber B., Calmy A., Battegay M., Cavassini M., Vernazza P., Caminada A.P., Rickenbach M., Bernasconi E.
Collaborateur(s)
Swiss HIV Cohort Study
Contributeur(s)
Barth J., Battegay M., Bernasconi E., Böni J., Bucher HC., Burton-Jeangros C., Calmy A., Cavassini M., Cellerai C., Egger M., Elzi L., Fehr J., Fellay J., Flepp M., Furrer H., Fux CA., Gorgievski M., Günthard H., Haerry D., Hasse B., Hirsch HH., Hirschel B., Hösli I., Kahlert C., Kaiser L., Keiser O., Kind C., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Müller N., Nadal D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schmid P., Schultze D., Schöni-Affolter F., Schüpbach J., Speck R., Taffé P., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S.
ISSN
1471-230X (Electronic)
ISSN-L
1471-230X
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
15
Pages
79
Langue
anglais
Notes
Publication types: Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
BACKGROUND: Hepatitis B virus (HBV) genotypes can influence treatment outcome in HBV-monoinfected and human immunodeficiency virus (HIV)/HBV-coinfected patients. Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antiretroviral therapy (ART) of HIV/HBV-coinfected patients. The influence of HBV genotypes on the response to antiviral drugs, particularly TDF, is poorly understood.
METHODS: HIV/HBV-co-infected participants with detectable HBV DNA prior to TDF therapy were selected from the Swiss HIV Cohort Study. HBV genotypes were identified and resistance testing was performed prior to antiviral therapy, and in patients with delayed treatment response (>6 months). The efficacy of TDF to suppress HBV (HBV DNA <20 IU/mL) and the influence of HBV genotypes were determined.
RESULTS: 143 HIV/HBV-coinfected participants with detectable HBV DNA were identified. The predominant HBV genotypes were A (82 patients, 57 %); and D (35 patients, 24 %); 20 patients (14 %) were infected with multiple genotypes (3 % A + D and 11 % A + G); and genotypes B, C and E were each present in two patients (1 %). TDF completely suppressed HBV DNA in 131 patients (92 %) within 6 months; and in 12 patients (8 %), HBV DNA suppression was delayed. No HBV resistance mutations to TDF were found in patients with delayed response, but all were infected with HBV genotype A (among these, 5 patients with genotype A + G), and all had previously been exposed to lamivudine.
CONCLUSION: In HIV/HBV-coinfected patients, infection with multiple HBV genotypes was more frequent than previously reported. The large majority of patients had an undetectable HBV viral load at six months of TDF-containing ART. In patients without viral suppression, no TDF-related resistance mutations were found. The role of specific genotypes and prior lamivudine treatment in the delayed response to TDF warrant further investigation.
Mots-clé
Adult, Aged, Antiviral Agents/therapeutic use, Coinfection/drug therapy, Coinfection/virology, Drug Resistance, Viral/genetics, Female, Genotype, HIV Infections/complications, HIV Infections/drug therapy, Hepatitis B/complications, Hepatitis B/drug therapy, Hepatitis B virus/genetics, Humans, Lamivudine/therapeutic use, Male, Middle Aged, Retrospective Studies, Switzerland, Tenofovir/therapeutic use, Viral Load/drug effects, Young Adult
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/07/2015 16:43
Dernière modification de la notice
20/08/2019 15:02
Données d'usage